India's
generic drug company launches two new anti-HIV products
30 November, 2005
An announcement has been made by Ranbaxy
Laboratories Limited (RLL) today about the introduction
of two new anti-HIV products, Virolis-E and Virocomb-E,
in India on World AIDS Day, December 1, 2005. Both products
contain three Anti-retroviral (ARV) drugs and offer
World Health Organization (WHO) recommended first line
Highly Active Anti Retroviral Therapy (HAART) in convenient
daily use packs.
Commenting on the launch, Dr. Brian
Tempest, CEO and Managing Director, RLL said, "We
are pleased to introduce Virolis-E and Virocomb-E, two
innovative products that aim to make HIV treatment easier
to administer and use. Ranbaxy is committed to HIV care
and this is yet another step in our endeavor to make
high quality, affordable and patient-friendly ARVs available
worldwide."
These Ranbaxy products are designed
to improve compliance with HAART, which is presently
a challenge faced by both patients and healthcare providers.
In most countries outside India, these products will
be labeled and sold under the Coviro-E and Avocomb-E
brand names respectively.
To read more, visit...
http://biz.yahoo.com/prnews/051130/nyw131.html?.v=34
|
